New hope for swelling disorder: experimental drug enters human trials
NCT ID NCT05691361
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 16 times
Summary
This study tests a new drug called ADX-324 for hereditary angioedema, a genetic condition that causes sudden, painful swelling attacks. The trial has two parts: first, healthy volunteers receive a single dose to check safety; second, patients with the condition receive multiple doses to see if the drug controls swelling. The goal is to find a safe and effective treatment to manage this chronic disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMAX Clinical Research
Adelaide, South Australia, 5000, Australia
Conditions
Explore the condition pages connected to this study.